KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Common Equity (2016 - 2025)

Historic Common Equity for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Common Equity fell 53.14% to $1.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year decrease of 53.14%. This contributed to the annual value of $1.9 billion for FY2025, which is 53.14% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Common Equity is $1.9 billion, which was down 53.14% from $1.9 billion recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Common Equity high stood at $2.6 billion for Q2 2021, and its period low was $1.7 billion during Q2 2025.
  • In the last 5 years, CRISPR Therapeutics AG's Common Equity had a median value of $1.9 billion in 2024 and averaged $2.0 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Common Equity soared by 18592.08% in 2021 and then plummeted by 2224.38% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Common Equity (Quarter) stood at $2.4 billion in 2021, then decreased by 21.84% to $1.9 billion in 2022, then increased by 0.39% to $1.9 billion in 2023, then grew by 2.62% to $1.9 billion in 2024, then decreased by 0.53% to $1.9 billion in 2025.
  • Its Common Equity stands at $1.9 billion for Q4 2025, versus $1.9 billion for Q3 2025 and $1.7 billion for Q2 2025.